Post-exposure treatment of Ebola virus disease in Guinea pigs using EBOTAb, an ovine antibody-based therapeutic

Stuart D. Dowall, Andrew Bosworth, Emma Rayner, Irene Taylor, John Landon, Ian Cameron, Ruth Coxon, Ibrahim Al Abdulla, Victoria A. Graham, Graham Hall, Gary Kobinger, Roger Hewson, Miles W. Carroll

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Ebola virus (EBOV) is highly pathogenic, with a predisposition to cause outbreaks in human populations accompanied by significant mortality. An ovine polyclonal antibody therapy has been developed against EBOV, named EBOTAb. When tested in the stringent Guinea pig model of EBOV disease, EBOTAb has been shown to confer protection at levels of 83.3%, 50% and 33.3% when treatment was first started on days 3, 4 and 5 post-challenge, respectively. These timepoints of when EBOTAb treatment was initiated correspond to when levels of EBOV are detectable in the circulation and thus mimic when treatment would likely be initiated in human infection. The effects of EBOTAb were compared with those of a monoclonal antibody cocktail, ZMapp, when delivered on day 3 post-challenge. Results showed ZMapp to confer complete protection against lethal EBOV challenge in the Guinea pig model at this timepoint. The data reported demonstrate that EBOTAb is an effective treatment against EBOV disease, even when delivered late after infection.

Original languageEnglish (US)
Article number30497
JournalScientific reports
StatePublished - Jul 28 2016
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Post-exposure treatment of Ebola virus disease in Guinea pigs using EBOTAb, an ovine antibody-based therapeutic'. Together they form a unique fingerprint.

Cite this